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Background: Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 ,
a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for
the treatment of metastatic melanoma. As a result of the up-regulation of the immune system, several immune-
mediated adverse effects have been reported including colitis, dermatitis, hepatitis and rarely hypophysitis. The
most frequent immune-mediated adverse effects described in literature include gastrointestinal toxicity such as
diarrhea, colitis and case of colitis and ileitis.
Case presentation: In this paper we report an interesting case of immune-mediate ileitis without colitis in a
54 years old woman with metastatic melanoma treated with ipilimumab. We also discuss about case management
and the possible pathological mechanisms considering also previous reports.
Conclusions: The aim of this article is to support further investigations concerning epigenetic and genetic analysis
in order to personalize biological therapy and to reduce immune related adverse events observed after ipilimumab
administration.
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Ipilimumab is a fully human monoclonal antibody direc-
ted against cytotoxic T-lymphocyte antigen-4 (CTLA-4),
a key negative regulator of T-cell activation approved
for the treatment of metastatic melanoma. The antibody
contributes to activate immune response against tumor
cells exploiting this mechanism of action. However, Ipili-
mumab treatment has been associated with severe and
potentially life-threatening immunological adverse ef-
fects due to T cell activation and proliferation. Most of
the serious adverse effects affect gastro-intestinal tract
and include diarrhea, colitis and colitis associated with
ileitis. In this paper we describe a case of immune-
mediate ileitis without colitis observed in a 54 years old
woman with metastatic melanoma after 3 cycles of
treatment with ipilimumab. We also report histological
and CT findings showing respectively extensive super-
ficial ulceration, full-thickness inflammatory infiltrate* Correspondence: o.venditti@unicampus.it
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unless otherwise stated.and indirect sign of ileum wall necrosis. These findings
demonstrate how an immune system disregulation in-
duced by Ipilimumab may result in severe and fatal
immune-mediated adverse reactions caused by T-cell acti-
vation and proliferation.
Case presentation
A 54 years old woman with previous history of malig-
nant cutaneus melanoma came to our attention in April
2013. In 2009 she had undergone surgery after the de-
tection of a nodular mass located in the right iliac fossa.
Pathology specimens were consistent with pigmented
nodular melanoma, with vertical growth, Clark level III,
Breslow tickeness of 9 mm. The excision margins were
negative. Right inguinal sentinel lymph node was positive
but a subsequent dissection excluded further lymphnodal
involvement (stage IIIB: pT4a, pN1a, pMx). A staging
Fluorodeoxyglucose-PET (FDG-PET) showed no local
or distant disease. Then patient started a follow up pro-
gram until January 2012, when a CT scan showed multiple
bilateral lung metastases and a FDG-PET scan revealed
pathological uptake in the right iliac fossa and lumbarl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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carried out with the detection of exon 15 mutation.
The patient started a first line treatment with Dabrafenib
(150 mg orally twice daily) from May 2012 to February
2013. The FDG-PET scan performed in October 2012
proved a complete metabolic response in right iliac fossa
and a partial response at L3 level; moreover, the CT scan
demonstrated a reduction in number and size of lung me-
tastases. In January 2013 a new FDG-PET scan showed
progressive disease in lung and bones (D11, L3, 4th right
rib and pelvis) and appearance of liver metastases. Subse-
quently patient started a second line treatment with Ipili-
mumab (3 mg/kg every 3 weeks planned for a total of 4
doses). On June 2013 two days after the third cycle of Ipi-
limumab she was admitted to our oncology unit reporting
fever (body temperature >38.5°C) without shiver, Grade 2
asthenia and nausea and Grade 1 diarrhea. The blood
cultures performed were negative for bacterial growth.
Administration of intravenous Metilprednisolone 2 mg/Kg
die was started with clinical benefit but without a com-
plete resolution of fever. Considering the significant
clinical benefit obtained, patient was dismissed with
prescription of oral prednisone 1 mg/kg daily. Given
previous toxicity and according to the drug schedule,
the 4th dose of ipilimumab was delayed until the toxic-
ities returned to Grade 0 or 1. After two weeks, in July
2013 the patient was admitted again to our oncology
unit for persisting and deteriorating Grade 3 asthenia,
Grade 2 nausea and vomiting, Grade 3 diarrhea and
dehydratation, despite of oral corticosteroid treatment.
Physical examination proved a poor hydration of skin
and mucosal membranes, a diffuse abdominal pain, in par-
ticular in the right iliac fossa; blood examination revealed
anemia (Hemoglobin- Hgb- 9.60 g/dL) and hypoalbumin-
emia (1.74 g/dL). During the hospital stay fluids, cortico-
steroids (metilprednisolone 2 mg/Kg die) and albumin
were administered with partial resolution of symptoms.
Few days later, clinical conditions worsened, because of
the development of gastrointestinal (GI) hemorrhage,Figure 1 CT axial image during venous phase. Figure A shows a marke
shows a thicker wall of the ileum, with the presence of air (arrow), which is
finding suggest the presence of necrosis of the ileum wall.severe anemia (Hgb 5.20 g/dL), thrombocytopenia (plate-
lets 52.00 ×10^3/uL) and coagulation impairment (INR
1.58). Red blood cells, platelet and plasma were transfused
with poor benefit. A CT scan of the abdomen was per-
formed in order to exclude an immune-mediated colitis
(described in literature as a possible side effect occurring
during ipilimumab treatment [1,2]) since no comorbidities
such as intestinal bowel disease or hematological disorder
were referred at the moment of hospital admission. Radio-
logical imaging showed colic mucosal hyperemia and sub-
mucosal edema (Figure 1).
In consideration of CT findings, a total colonscopy
was performed detecting red blood in rectal ampulla and
sigmoid colon, without mucosal alterations and a hy-
peremic and edematous colic mucosa with extensive loss
of substance. Terminal ileum biopsies confirmed the
presence of superficial loss of substance, and an intense
inflammatory infiltrate rich of lymphocytes and granulo-
cytes with sporadic cryptic abscesses extending up to the
muscolaris mucosae tonaca. Since gastrointestinal (GI)
bleeding did not stop with medical therapy, the patient
underwent surgery. A subtotal colectomy with resection
of the last tract of terminal ileum was performed, with
the small bowel appearing necrotic and perforated in
several points for at least 40 cm of length (Figure 2).
Pathology report showed extensive superficial ulceration
and full-thickness inflammatory infiltrate rich of lym-
phocytes, granulocytes and eosinophils, associated with
acute sierosytis and vessels rupture (Figure 3). None of
these findings were observed in the colic tract, where it
has been found normal colic mucosa and glands without
inflammatory infiltrate or ulceration (Figure 4). The pa-
tient continued steroid therapy with metilprednisolone
2 mg/Kg iv die, and no further episodes of diarrhea or
GI bleeding were reporter after surgery. A post-operative
CT scan showed disease progression in all sites previously
detected and appearance of diffuse peritoneal carcinoma-
tosis. In consideration of these findings, the patients was
addressed to a palliative care program.d wall thickness (arrow) at the level of pre terminal ileum. Figure B
a typical sign of pneumatosis intestinalis, the lume is enlarged. These
Figure 2 The picture show the last tract of ileum resected; as
seen in this image the small bowel appearing necrotic and
perforated in several points for at least 40 cm of length.
Figure 4 Colon biopsy from the colonoscopy. The pathology
report describes normal colonic mucosa fragment with colic glands
without inflammatory infiltrate or ulceration.
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Treatment of stage IV melanoma patients needs to be
discussed by interdisciplinary tumor board in centers
with broad experience for the disease.
Several studies investigating the mechanism of the
pathogenesis identified multiple pathways to be involved
in cellular invasion and drug resistance [3,4].
Cytotoxic drugs such as dacarbazine (DTIC), temozo-
lomide, taxanes, fotemustine [5] and platin are currently
considered valid choices in the management of meta-
static melanoma even if new therapeutic strategies such
as immunotherapy using Ipilimumab or anti-PD1 anti-
bodies, selective BRAF inhibitors like vemurafenib and
dabrafenib, c-Kit inhibitors and MAPK/ERK kinase
(MEK) inhibitors have demonstrated an impressive anti-
tumor activity in clinical trials.
Ipilimumab is a fully human monoclonal antibody direc-
ted against cytotoxic T-lymphocyte antigen-4 (CTLA-4),
a key negative regulator of T-cell activation. CTLA4 is
constitutively expressed on inhibitory CD25+ CD4+ re-
gulatory T cells (Treg) and plays a key role in Treg con-
trol of the immune response. CTLA-4 thereby works asFigure 3 Terminal ileum biopsies of the last small bowel tract resecte
full-thickness inflammatory infiltrate rich of lymphocytes, granulocytes and
(panel A and C).a physiologic “brake” on the activated immune system.
Monoclonal antibody against CTLA-4, such as Ipilimu-
mab, prevent this feedback inhibition, enhancing the im-
mune response against the tumor [6]. A disregulation of
the immune system induced by Ipilimumab may pro-
duce severe and fatal immune-mediated adverse reac-
tions due to T-cell activation and proliferation. Potentially,
any organ system may be involved but the most common
reported irAEs are enterocolitis, hepatitis, dermatitis
(including toxic epidermal necrolysis), neuropathy, and
endocrinopathy.
In a phase III trial demonstrating an increase in
survival, immune-related adverse events occurred in
approximately 60 percent of patients treated with ipi-
lumumab; they usually tended to appear after several
weeks of treatment. Overall, severe or life-threatening
(grade 3 or 4) toxicities were seen in 10 to 15 percent
of ipilimumab-treated patients, compared to 3 percent
in those receiving only gp100. The most frequent irAEs
described in literature include GI AEs such as diarrhea
and colitis.d. Pathology showed extensive superficial ulceration (panel B) and
eosinophils, associated with acute serositis and vessels rupture
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(diarrhea of 7 or more stools above baseline, fever, peri-
toneal signs; Grade 3–5) immune-mediated enterocolitis
occurred in 34 (7%) patients and moderate (diarrhea with
up to 6 stools above baseline, abdominal pain, mucus
or blood in stool) Grade 2 both ileitis and colitis oc-
curred in 28 (5%) Ipilimumab-treated patients. Across
all Ipilimumab-treated patients (n = 511), 5 (1%) pa-
tients developed intestinal perforation, 4 (0.8%) patients
died as a result of complications, and 26 (5%) patients
were hospitalized for severe enterocolitis [7].
Although clinical presentation is similar to inflamma-
tory bowel disease (IBD), lesions distribution and patho-
logical characteristics are different from Crohn’s disease
(CD), ulcerative colitis (UC) or graft-versus host disease.
The predominantly diffuse nature of the active inflam-
mation in colonic biopsies from patients after onset of
diarrhea or colitis are similar to ulcerative colitis but fea-
tures of chronicity and diffuse colonic involvement dis-
tally (hallmarks of UC) were not observed. Not of all
were the distinctive features of CD, including granulomas,
aphthous or fissuring ulcers, and bowel wall thickening
secondary to transmural inflammation. CD is primarily a
disease of the proximal colon and terminal ileum whereas
the majority of abnormal histologic findings in patient
treated with Ipilimumab were located distally; finally, the
histologic findings observed were also distinct from graft-
vs.-host disease, which is characterized by prominent epi-
thelial apoptosis and glandular destruction [8].
Berman D. et al. tried to explain these different patho-
logical findings in a recent study showing that blockade
of CTLA-4 by Ipilimumab may cause disregulation of
GI mucosal immunity as pointed out by fluctuating an-
tibody titers against enteric flora, increased levels of
neutrophil-derived fecal calprotectin, and immune infil-
tration into the mucosa. This autoimmune deregulation
is completely different from those observed for classic
IBD; the pattern of positive antibody against enteric
flora observed in this study was not consistent with that
for classic UC or CD. In CD, approximately half of pa-
tients are positive for anti-Saccharomyces cerevisiae
antibody (ASCA), CBir flagellin antibody (anti-CBir1),
and anti-I2, and <25% are positive for perinuclear anti-
neutrophil cytoplasmic antibody (pANCA); in UC, ap-
proximately half of patients are positive for pANCA,
but <10% are positive for ASCA, anti-CBir1, anti-I2, and
antiOmpC [9]. In this study, the most common positive ti-
ters in patients with grade 2 or higher irAEs were to
pANCA and antiOmpC, with <10% of patients positive
for anti-I2 and ASCA, and <15% positive for anti-CBir1.
Finally, the fluctuating antibody titers observed in this
study were also inconsistent with CD, where titers are
stable over time and despite changes in disease activity.
This fluctuation may reflect changes in the state ofT-cell activation as Ipilimumab concentrations cross
an unidentified threshold. The parallel and transient
changes in antibody levels in conjunction with an in-
crease in fecal calprotectin are consistent with dysreg-
ulated mucosa induced by CTLA-4 blockade in these
non-IBD patients [10].
The autoimmune disregulation reported by some pa-
tient treated with iplimumab can be explained by com-
mon genetic variation in the CTLA4 gene. Sanderson
et al., hypothesized that the GG allele of rs7565213
(JO30), reported to have lower CTLA4 activity, cor-
relates with a higher change of developing autoimmune
symptoms and subsequently could be associated with
improved prognosis. In their study of 19 patients, 3 out
of 4 patients with the GG allele developed autoimmune
symptoms [11]. Despite these interesting data, a subse-
quent study did not confirm this hypothesis since a sig-
nificant association between the G allele of re7565213
(JO30) and the development of autoimmune reactions
was not observed [12].
In the present case report we describe an interesting
case of immune-mediate ileitis without colitis secondary
to Ipilimumab administration.
We strongly suggest clinician to consider inflamma-
tory ileitis in differential diagnosis when the patients
present persistent diarrhea/ bloody diarrhea and abdom-
inal pain in the right iliac fossa when colitis is ruled out
with colonoscopy, in order to better optimize surgical
treatment if necessary.
Since the patient developed only ileitis without colitis -
as reported in the most of patient in the phase III study -
we can suppose that two different autoimmune pathways
could be activated against colic and ileal epitopes.
Further data are needed to establish which ileal cell
epitopes and which specific subpopulation of the enteric
flora was the main target of Ipilimumab damage. A bet-
ter understanding of Ipilimumab immune related path-
way with the view of identifying a specific immune T cell
subpopulation involved in these adverse reactions would
also be of great interest.Consent
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